



New Formulation for Acute and Chronic Inflammatory Diseases

Guest Editors:

Prof. Dr. Ana C. Calpena

Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain

Dr. Marcelle Silva-Abreu

1. Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain
2. Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain

Deadline for manuscript submissions:

closed (30 April 2022)

Message from the Guest Editors

Inflammation is the process by which the immune system recognizes and removes harmful stimuli and initiates the healing process. Inflammation can be divided into two types, acute and chronic, the latter being able to contribute to a wide range of diseases such as intestinal diseases, diabetes, asthma, osteoarthritis, cardiovascular diseases, allergies, Alzheimer's, autoimmune disorders, and lung diseases, among others. Different alternatives of pharmaceutical formulations have been used for the treatment where inflammation has its main role, as well as drug delivery systems, including liposomes, nanoparticles (lipid and polymeric), nanocrystals, dendrimers, niosomes, and micelles. In addition, dosage forms such as semi-solid, solid, liquid, oral and topical formulations have historically been used with excellent results. This Special Issue serves to highlight and capture the continuous progress and the current situation of different new pharmaceutical formulations for the treatment of inflammatory diseases. We invite articles on all aspects of acute and chronic inflammation using different pharmaceutical formulations, including diverse routes of administration.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma